文献速递浆细胞疾病

MAIA研究:不适合移植新诊断多发性骨髓瘤患者健康相关生活质量分析

Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial.
PubMed 文献 · J Clin Oncol · 2020-12-16

MAIA III期研究评估D-Rd与Rd在不适合移植新诊断多发性骨髓瘤患者中的患者报告结局。共737例随机分组,D-Rd组在总体健康状况和疼痛改善方面优于Rd组,且不受年龄、ECOG评分或缓解深度影响。

要点

  • D-Rd较Rd在总体健康状况上持续更优,各时间点均一致
  • D-Rd从第3周期起显著降低疼痛评分,并持续至第12周期
  • 疼痛改善具有临床意义,不受年龄、ECOG或缓解深度影响

核心结论

  • D-Rd较Rd在不适合移植新诊断多发性骨髓瘤患者中带来更快且持续、有临床意义的患者报告结局改善,包括疼痛。

研究设计与样本

  • III期MAIA研究,737例不适合移植新诊断多发性骨髓瘤患者随机分配至D-Rd组(n=368)或Rd组(n=369)。
  • 采用EORTC QLQ-C30和EQ-5D量表在基线和治疗期间每3个月评估患者报告结局。

主要发现

  • 两组EORTC QLQ-C30总体健康状况评分较基线改善,D-Rd组在所有时间点均持续更优。
  • D-Rd组的疼痛改善在年龄、ECOG评分或缓解深度各亚组中均具有临床意义。
  • 两组EQ-5D视觉模拟量表评分均观察到患者报告结局改善。

关键数值与推荐

  • 患者报告结局评估依从性:基线>90%,至第12个月>78%(两组)。
  • D-Rd组总体健康状况获益不受年龄(<75岁和≥75岁)、基线ECOG评分或缓解深度影响。

临床怎么用

  • 对于不适合移植的新诊断多发性骨髓瘤患者,D-Rd方案在改善总体健康状况和疼痛方面优于Rd,可支持临床决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the effects of daratumumab, lenalidomide, and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) on patient-reported outcomes (PROs) in the phase III MAIA study. PATIENTS AND METHODS: PROs were assessed on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30-item and the EuroQol 5-dimensional descriptive system at baseline and every 3 months during treatment. By mixed-effects model, changes from baseline are presented as least squares means with 95% CIs. RESULTS: A total of 737 transplant-ineligible (TIE) patients with newly diagnosed multiple myeloma were randomly assigned to D-Rd (n = 368) or Rd (n = 369). Compliance with PRO assessments was high at baseline (> 90%) through month 12 (> 78%) for both groups. European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30-item global health status scores improved from baseline in both groups and were consistently greater with D-Rd at all time points. A global health status benefit was achieved with D-Rd, regardless of age (< 75 and ≥ 75 years), baseline Eastern Cooperative Oncology Group (ECOG) performance status score, or depth of response. D-Rd treatment resulted in significantly greater reduction in pain scores as early as cycle 3 (P = .0007 v Rd); the magnitude of change was sustained through cycle 12. Reductions in pain with D-Rd were clinically meaningful in patients regardless of age, ECOG status, or depth of response. Similarly, PRO improvements were observed with D-Rd and Rd on the EuroQol 5-dimensional descriptive system visual analog scale score. CONCLUSION: D-Rd compared with Rd was associated with faster and sustained clinically meaningful improvements in PROs, including pain, in transplant-ineligible patients with newly diagnosed multiple myeloma regardless of age, baseline ECOG status, or depth of treatment response.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Perrot A, Facon T, Plesner T, et al. Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial. J Clin Oncol. 2020. PMID: 33326255. doi:10.1200/JCO.20.01370

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。